Therapeutic Advances in Medical Oncology最新文献

{"title":"Extracellular vesicles-derived extracellular RNA in bladder cancer: current progress and future prospects.","authors":"Jinbang Chen, Xin Yang, Zihan Hao, Hongqian Guo, Ying Sun, Rong Yang","doi":"10.1177/17588359251349288","DOIUrl":"10.1177/17588359251349288","url":null,"abstract":"<p><p>Bladder cancer (BCa), ranked as the 10th most common malignancy worldwide, presents significant challenges due to its high recurrence rates and clinical heterogeneity. The current standard diagnostic methods, cystoscopy and urine cytology, demonstrate limited sensitivity, particularly for low-grade tumors, highlighting the urgent need for minimally invasive biomarkers. Extracellular vesicles (EVs), membrane-bound nanoparticles that carry extracellular RNA (exRNA), have emerged as critical players in BCa diagnostics and therapeutics. Recent advancements show that EVs-exRNA facilitates early detection, dynamic monitoring of disease progression, and prognosis prediction. EVs-exRNA, as promising biomarkers, have made substantial progress in BCa research. In this review, we examine the role of EVs-exRNA in BCa, investigate its diagnostic and prognostic value and discuss the challenges and future directions for its clinical application, aiming to provide new insights for future research in this field.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251349288"},"PeriodicalIF":4.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of delayed addition of PD-1/PD-L1 inhibitors to chemotherapy on outcomes in patients with extensive-stage small cell lung cancer.","authors":"Shuangqing Lu, Chao Wang, Xiaoyang Zhai, Zhuoran Sun, Ke Zhao, Dawei Chen, Hui Zhu","doi":"10.1177/17588359251356919","DOIUrl":"10.1177/17588359251356919","url":null,"abstract":"<p><strong>Background: </strong>Immunotherapy combined with chemotherapy is the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). However, the effect of delayed initiation of immunotherapy on its efficacy remains unclear.</p><p><strong>Objectives: </strong>This study aimed to investigate the impact of the delayed addition of programmed death receptor 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors on treatment outcomes in patients with ES-SCLC.</p><p><strong>Design: </strong>This retrospective cohort study used propensity score matching (PSM) to balance baseline characteristics.</p><p><strong>Methods: </strong>This study included 416 patients with ES-SCLC who received first-line immunotherapy between January 2020 and December 2022. Patients were categorized into two groups: delayed-immunotherapy (IO) (PD-1/PD-L1 inhibitors initiated during the 2nd or 3rd chemotherapy cycle) and early-IO (immunotherapy initiated during the first cycle). A 1:1 PSM was performed to balance baseline characteristics. The primary endpoints were overall survival (OS) and progression-free survival (PFS), which were analyzed using the Kaplan-Meier method and compared using log-rank tests.</p><p><strong>Results: </strong>Owing to the exclusion of PD-L1/PD-1 inhibitors from medical insurance, financial constraints, and poor physical condition of some patients, 72 patients were included in the delayed-IO group (second cycle: 41; third cycle: 31), while 344 were in the early-IO group. Before PSM, median OS and PFS in the delayed-IO group were 24.00 and 8.75 months, compared to 18.59 and 7.57 months in the early-IO group, with no significant differences (OS: HR 0.72, <i>p</i> = 0.054; PFS: HR 0.86, <i>p</i> = 0.281). After PSM (72 patients per group), the delayed-IO group showed significantly longer median OS (24.00 vs 18.79 months, HR 0.60, 95% CI 0.38-0.97, <i>p</i> = 0.037) and PFS (8.75 vs 6.49 months, HR 0.69, 95% CI 0.48-0.99, <i>p</i> = 0.044) compared to the early-IO group. These results suggest that, in specific patient populations, delayed immunotherapy may improve survival outcomes by optimizing patient condition or treatment response.</p><p><strong>Conclusion: </strong>In patients with ES-SCLC, delayed administration of PD-1/PD-L1 inhibitors during the second to fourth chemotherapy cycles improves survival outcomes compared to concurrent administration during the first cycle, with a similar safety profile. These results suggest that, in specific patient populations, delayed immunotherapy may improve survival outcomes by optimizing patient condition or treatment response.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251356919"},"PeriodicalIF":4.3,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12280550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitors improve the efficacy of neoadjuvant chemotherapy in advanced gastric cancer: a retrospective cohort study.","authors":"Yonghe Chen, Yi Lin, Yingying Xu, Jianwei Zhang, Shi Chen, Shuai Ye, Gang Liu, Lei Lian, Junsheng Peng","doi":"10.1177/17588359251346423","DOIUrl":"10.1177/17588359251346423","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in metastatic gastric cancer. Their potential benefits in the neoadjuvant therapy for advanced gastric cancer (AGC) are promising but require real-world evidence.</p><p><strong>Objective: </strong>We aimed to assess the real-world impact of adding ICIs to neoadjuvant chemotherapy (NAC) in AGC patients.</p><p><strong>Design: </strong>This is a retrospective, propensity score-matched analysis of 580 AGC patients treated with NAC, with or without ICIs, followed by radical gastrectomy.</p><p><strong>Methods: </strong>Patients were matched using propensity score matching (PSM) to balance baseline characteristics. Pathological complete response (pCR) rates and toxicity were compared between the ICIs-Chemo and Chemo cohorts.</p><p><strong>Results: </strong>After PSM, 188 patients were included: 71 in the ICIs-Chemo cohort and 117 in the Chemo cohort. Chemotherapy regimens in both cohorts included SOX (49.5%, 93/188), FLOT (26.6%, 50/188), XELOX (12.8%, 24/188), and FOLFOX (11.2%, 21/188). The ICIs used were predominantly Sintilimab (67.6%, 48/71), followed by Tislelizumab (21.1%, 15/71), Nivolumab (7%, 5/71), and others (4.2%, 3/71). Adding ICIs to NAC significantly improved the pCR rate (ICIs-Chemo: 29.6% vs. Chemo: 13.7%, <i>p</i> = 0.014). The SOX regimen, with (37.1%, 13/35) or without ICIs (22.4%, 13/58), demonstrated the highest pCR rates. Subgroup analysis indicated that patients older than 60 years (OR = 3.86, <i>p</i> < 0.01) and those with moderately/well-differentiated tumors (OR = 4.27, <i>p</i> = 0.01) may derive greater benefit from adding ICIs. While overall toxicity and surgical complication rates were similar between cohorts, we observed two cases of suspected severe immune-related adverse events (irAEs).</p><p><strong>Conclusion: </strong>Adding ICIs to NAC regimens in AGC significantly improves pathological response. While overall toxicity is not increased, close monitoring for irAEs is necessary.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251346423"},"PeriodicalIF":4.3,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The IASLC uncertain resection, general overview, current evidence, and future prospects: a systematic review and meta-analysis.","authors":"Mingming Hu, Xiaomi Li, Maike Zheng, Jiaqi Yu, Baohua Lu, Ying Wang, Xiaoqing Cao, Chongyu Su, Yujie Dong, Xu Zhang, Tongmei Zhang","doi":"10.1177/17588359251344789","DOIUrl":"10.1177/17588359251344789","url":null,"abstract":"<p><strong>Background: </strong>Introduced by the International Association for the Study of Lung Cancer (IASLC) in 2005, uncertain resection (Run) categorizes a new subclass of residual tumor. Despite several studies, the prognostic significance of Run in operable non-small cell lung cancer (NSCLC) remains unclear.</p><p><strong>Objectives: </strong>This study aimed to investigate the prognostic influence of Run in operable NSCLC, focusing on the impact of the four elements that comprise R descriptors on patient survival.</p><p><strong>Design: </strong>A systematic review and meta-analysis were conducted to synthesize data from relevant clinical studies.</p><p><strong>Methods: </strong>We developed search strategies to identify relevant clinical studies across databases including PubMed, Embase, Cochrane Library, Web of Science, CNKI, and Wanfang up to June 2024. Quantitative analysis was performed with Stata 15 to investigate the prognostic influence of Run, the extent of mediastinal lymph node removal, and the highest mediastinal lymph node involvement (HMLI). We also summarized the main findings from studies on pleural lavage cytology (PLC) and carcinoma in situ in operable NSCLC.</p><p><strong>Results: </strong>Compared to complete resection, Run-associated patients exhibited inferior 5-year overall survival (OS) and disease-free survival (DFS; risk ratio (RR) = 1.31, 95% confidence interval (CI) 1.19-1.44; RR = 1.43, 95% CI 1.28-1.60). Limited lymphadenectomy (L-LA) in cI stage showed similar survival benefit (OS, RR = 0.97, 95% CI 0.90-1.06; DFS, RR = 1.06, 95% CI 0.97-1.15), in contrast with systematic lymph node dissection (SLND). For pN2-III patients, HMLI indicated poorer OS (hazard ratio (HR) = 1.22, 95% CI 1.14-1.31) and DFS (HR = 1.25, 95% CI 1.14-1.36).</p><p><strong>Conclusion: </strong>IASLC's residual tumor classification correlated with significant survival differences. Compared with R0, Run was associated with inferior 5-year OS and DFS. L-LA seemed to provide equivalent survival benefits, in contrast to SLND. For patients with low invasiveness in stage cI, L-LA could be considered as a preferred option. HMLI predicts poorer survival in pN2-III patients, and positive PLC significantly worsened long-term survival in operable NSCLC, particularly at early stage.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251344789"},"PeriodicalIF":4.3,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12264421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertility preservation in young patients with breast cancer: insights from the Gemme Dormienti network.","authors":"Gabriella Gentile, Cristiano Tesei, Stefania Brunetti, Paola Cavaceppi, Giuseppe Sorrenti, Matteo Lambertini, Mariavita Ciccarone","doi":"10.1177/17588359251341210","DOIUrl":"10.1177/17588359251341210","url":null,"abstract":"<p><strong>Background: </strong>Fertility preservation (FP) is a key aspect of care for young women with breast cancer (BC), as oncologic treatments can compromise future reproductive potential. Early counseling and access to FP strategies are essential to support long-term quality of life.</p><p><strong>Objectives: </strong>To evaluate the uptake of FP counseling, the choice of preservation techniques, and reproductive outcomes in women aged 18-39 years with BC.</p><p><strong>Design: </strong>A retrospective single-center cohort study was conducted at the Gemme Dormienti network between 2018 and 2023.</p><p><strong>Methods: </strong>A total of 100 BC patients underwent baseline ovarian reserve assessments, including hormonal and ultrasound evaluations. All received gonadotropin-releasing hormone agonist therapy prior to chemotherapy. Data on FP strategies-oocyte and/or ovarian tissue cryopreservation (OTC)-and pregnancy outcomes were collected.</p><p><strong>Results: </strong>Fifty-four percent of patients pursued FP procedures: 35% underwent oocyte cryopreservation, 55% OTC, and 10% both. Younger patients (18-29 years) were more likely to opt for combined techniques. Pregnancy rates were highest among women aged 35-39. Ovarian reserve indicators, including antral follicle count and endometrial thickness, showed an age-related decline.</p><p><strong>Conclusion: </strong>This study highlights the importance of early, personalized FP counseling for young BC patients. Age significantly influences both FP choices and reproductive outcomes, reinforcing the need to integrate fertility discussions into initial cancer care.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251341210"},"PeriodicalIF":4.3,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A <i>POLR1D</i>-regulating single-nucleotide polymorphism as a predictive marker candidate for platinum-based chemotherapy in gastrointestinal cancers.","authors":"Takahiro Mori, Kazuko Ueno, Masao Nagasaki, Koichi Matsuda","doi":"10.1177/17588359251355079","DOIUrl":"10.1177/17588359251355079","url":null,"abstract":"<p><strong>Background: </strong>Platinum-based compounds have been instrumental in clinical oncology, underscoring the critical need to identify predictive biomarkers for these agents to advance personalized medicine.</p><p><strong>Objectives: </strong>This study aimed to identify predictive biomarkers for platinum-based chemotherapies in gastrointestinal cancers.</p><p><strong>Design: </strong>This study was designed to explore candidate single-nucleotide polymorphisms (SNPs) through a genome-wide association study (GWAS), followed by re-evaluation using external nationwide cohorts. Subsequently, the biological functions of the selected SNPs were analyzed utilizing the online multi-omics databases.</p><p><strong>Methods: </strong>First, we conducted a GWAS in a discovery cohort of esophageal cancer (EC) patients undergoing platinum-based chemoradiation therapy, followed by Cox proportional-hazards analyses for overall survival and progression-free survival. Potential candidate polymorphisms identified in the discovery phase were validated in an external cohort derived from the nationwide BioBank Japan (BBJ).</p><p><strong>Results: </strong>Validation analysis revealed a significant association between the T allele of rs12876842 and tumor control rates in a gastric cancer cohort (<i>p</i> = 0.006). In other BBJ cohorts, including the chemoradiotherapy-treated BBJ-EC cohort, the odds ratio trends were consistent with the hazard ratios observed in the discovery cohort, indicating concordance of the risk allele across cancer types, although statistical significance was not reached. Analysis of online databases suggests that the C allele, identified as a risk allele, exhibits higher binding affinity to KLF4, while POLR1D, a downstream target of KLF4, may contribute to adverse prognostic signatures across multiple cancers. Besides, a significant association between genotype of rs12876842 and <i>POLR1D</i> expression in the gastroesophageal junction is confirmed in Genome Tissue Expression (<i>p</i> = 0.0000113), and prior studies have linked <i>POLR1D</i> expression with disease progression, neoplastic transformation, chemotherapy resistance, and poor clinical outcomes in various malignancies.</p><p><strong>Conclusion: </strong>Given the centrality of platinum-based drugs in cancer therapy, our findings align with biochemical evidence and prior literature, highlighting rs12876842 as a promising prognostic biomarker.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251355079"},"PeriodicalIF":4.3,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.","authors":"Mingjun Rui, Yingcheng Wang, Qiran Wei, Joyce H S You","doi":"10.1177/17588359251356109","DOIUrl":"10.1177/17588359251356109","url":null,"abstract":"<p><strong>Background: </strong>Talazoparib plus enzalutamide showed significant improvement of progression-free survival in metastatic castration-resistant prostate cancer (mCRPC) patients with alterations in homologous recombination repair (HRR) genes.</p><p><strong>Objectives: </strong>This study aimed to evaluate the cost-effectiveness of HRR status-guided use of talazoparib plus enzalutamide in patients with mCRPC from the U.S. payer perspective.</p><p><strong>Design: </strong>A partitioned survival model was used to simulate outcomes of a hypothetical cohort of mCRPC patients.</p><p><strong>Methods: </strong>Three treatment strategies were evaluated: (1) talazoparib plus enzalutamide for HRR-deficient patients and enzalutamide for non-HRR-deficient patients (HRR-guided talazoparib plus enzalutamide), (2) talazoparib plus enzalutamide for patients with or without HRR deficiency (empirical talazoparib plus enzalutamide), and (3) enzalutamide for patients with or without HRR deficiency (empirical enzalutamide). Primary outcomes were direct medical costs, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost per QALY gained (incremental cost-effectiveness ratio, ICER). Sensitivity analyses were performed to examine the robustness of model results.</p><p><strong>Results: </strong>In base-case analysis, the empirical enzalutamide strategy had the lowest cost and QALYs gained (US$752,383; 2.4764 QALYs), followed by HRR-guided talazoparib plus enzalutamide (US$878,517; 2.6490 QALYs), and empirical talazoparib plus enzalutamide (US$1,201,221; 2.8418 QALYs). The ICER of the HRR-guided talazoparib plus enzalutamide group (vs empirical enzalutamide) was US$730,671 per QALY gained, and the ICER of empirical talazoparib plus enzalutamide (vs HRR-guided talazoparib plus enzalutamide) was US$1,673,457 per QALY gained. Both ICERs of the HRR-guided strategy and empirical combination therapy were higher than the willingness-to-pay threshold (US$100,000 per QALY) and were not accepted as cost-effective. Sensitivity analyses found drug costs of talazoparib and enzalutamide to be the key influential factors on the cost-effectiveness of HRR-guided therapy.</p><p><strong>Conclusion: </strong>HRR-guided talazoparib plus enzalutamide does not appear to be cost-effective for mCRPC patients from the U.S. payer perspective.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251356109"},"PeriodicalIF":4.3,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Removal: \"Severe refractory colitis after intraperitoneal infusion of CEA-directed CAR T cells in patients with colorectal cancer\".","authors":"","doi":"10.1177/17588359251345270","DOIUrl":"https://doi.org/10.1177/17588359251345270","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1177/17588359241309825.].</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251345270"},"PeriodicalIF":4.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaginal health in breast cancer survivors: a practical clinical approach.","authors":"Maya Ram-Weiner, Shani Paluch-Shimon, Tanir M Allweis, Ahinoam Lev-Sagie","doi":"10.1177/17588359251344007","DOIUrl":"10.1177/17588359251344007","url":null,"abstract":"<p><p>Thanks to advanced treatments, many breast cancer (BC) patients become long-term survivors, yet suffer a diminished quality of life (QOL) due to estrogen deprivation. This affects adherence to endocrine treatments, potentially compromising outcomes. While there is increasing recognition of genitourinary side effects, vulvovaginal health remains under-addressed. Many clinicians overlook the impact of endocrine therapy on the genitourinary system and lack knowledge about safe and effective treatments, leading to undertreatment and aggravated symptoms. Proper treatments not only boost the QOL but also enhance endocrine therapy adherence, directly influencing long-term outcomes. We offer an updated review and guidelines on vulvovaginal health for BC survivors. Our review details the genitourinary hypoestrogenic state, its effects on the genitourinary system, its diagnosis, as well as the safety, effectiveness, and available treatment options for BC patients. Furthermore, we offer practical recommendations for managing vulvovaginal symptoms, considering underlying mechanisms and the safe use of topical estrogen, with attention to receptor and cancer status.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251344007"},"PeriodicalIF":4.3,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Camrelizumab plus SOX chemotherapy as adjuvant therapy for pathological stage III gastric or gastroesophageal junction adenocarcinoma: a prospective, multicenter, single-arm, phase II trial.","authors":"Hailong Jin, Jiren Yu, Yuan Gao, Xiaosun Liu, Hongtao Xu, Haiping Jiang, Shenkang Zhou, Nong Xu, Yulong Zheng, Qianyun Shen, Zhicheng Zhao, Dan Wu, Qing Zhang, Kankai Zhu","doi":"10.1177/17588359251355781","DOIUrl":"10.1177/17588359251355781","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors have shown promising results in the treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.</p><p><strong>Objectives: </strong>To evaluate the safety and efficacy of camrelizumab combined with S-1 plus oxaliplatin chemotherapy in the postoperative setting for pathological stage III (pStage III) G/GEJ adenocarcinoma.</p><p><strong>Design: </strong>This study was a prospective, multicenter, single-arm, phase II trial.</p><p><strong>Methods: </strong>Patients with pStage III G/GEJ adenocarcinoma were enrolled, receiving camrelizumab (200 mg), followed by oxaliplatin (130 mg/m²), both administered on day 1 of each 21-day cycle, and tegafur-gimeracil-oteracil potassium capsules (40-60 mg, twice daily) for 2 weeks, followed by a 7-day rest period. A total of eight treatment cycles were planned. The primary endpoints were the incidence of any-grade and grade 3 or 4 adverse events. The secondary endpoints were disease-free survival (DFS), overall survival (OS), and treatment completion rate.</p><p><strong>Results: </strong>Between September 2020 and March 2023, 52 patients were enrolled at three medical centers in Zhejiang Province, China. All 52 patients (100%) experienced treatment-related adverse events (TRAEs). Grade 3 or higher TRAEs were reported in 35 patients (67.3%). Events occurring in >10% of the patients included decreased neutrophil count, neutropenia, leukopenia, thrombocytopenia, and anemia. Eleven (21.2%) patients experienced TRAEs that led to the interruption or discontinuation of camrelizumab, including rash (1), hypothyroidism (1), hyperkalemia (1), interstitial pneumonia (2), cystitis or urethritis (2), and reactive cutaneous capillary endothelial proliferation (4). The actual 2-year DFS and OS rates were 82.4% and 86.3%, respectively, whereas the estimated 3-year DFS and OS rates were 69.1% and 71.3%, respectively.</p><p><strong>Conclusion: </strong>Camrelizumab combined with chemotherapy has a manageable and tolerable safety profile as an adjuvant treatment for pStage III G/GEJ adenocarcinoma. However, careful patient selection is necessary to identify patients most likely to benefit from combination therapy.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov registry: NCT04515615; Date of registration: August 14, 2020; Weblink: https://clinicaltrials.gov/study/NCT04515615.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251355781"},"PeriodicalIF":4.3,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}